ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019
05 Novembro 2019 - 7:00PM
ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a
clinical-stage biopharmaceutical company developing innovative
therapies by encapsulating therapeutic drug substances inside red
blood cells, today announced that it will host a
Third Quarter 2019 conference call and webcast on Friday, November
8, 2019, at 2:30 PM CET/8:30 AM EST to discuss operational
highlights.
The call is accessible via the below
teleconferencing numbers, followed by the Conference ID#:
7394954#
USA/Canada: +1 (833) 818-6807 |
France: +33 1 70 80 71 53 |
International Dial-In Number: +1 (409)
350-3501 |
United-Kingdom: +44 2031070289 |
The webcast can be followed live online via the
link: https://edge.media-server.com/mmc/p/irt7vk6s
An archived replay of the call will be available for 7 days by
dialing + 1 855 859 2056, Conference ID:
7394954#.
An archive of the webcast will be available on
ERYTECH’s website, under the “Investors” section
at investors.erytech.com
About ERYTECH and eryaspase:
www.erytech.com
ERYTECH is a clinical-stage biopharmaceutical
company developing innovative red blood cell-based therapeutics for
severe forms of cancer and orphan diseases. Leveraging its
proprietary ERYCAPS platform, which uses a novel technology to
encapsulate drug substances inside red blood cells, ERYTECH is
developing a pipeline of product candidates for patients with high
unmet medical needs. ERYTECH’s primary focus is on the development
of product candidates that target the altered metabolism of cancer
cells by depriving them of amino acids necessary for their growth
and survival.
The Company’s lead product candidate, eryaspase,
which consists of L-asparaginase encapsulated inside donor-derived
red blood cells, targets the cancer cell’s altered asparagine and
glutamine metabolism. Eryaspase is in Phase 3 clinical development
for the treatment of second-line pancreatic cancer and in Phase 2
for the treatment of triple-negative breast cancer. An
investigator-sponsored Phase 2 study in acute lymphoblastic
leukemia is ongoing in the Nordic countries of Europe.
ERYTECH produces its product candidates for
treatment of patients in Europe at its GMP-approved manufacturing
site in Lyon, France, and for patients in the United States at
its recently opened GMP manufacturing site in Princeton, New
Jersey, USA.
ERYTECH is listed on the Nasdaq Global Select
Market in the United States (ticker: ERYP) and on
the Euronext regulated market in Paris (ISIN code:
FR0011471135, ticker: ERYP). ERYTECH is part of the
CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC
All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
CONTACTS
ERYTECH
Eric SoyerCFO & COO |
NewCapMathilde Bohin / Louis-Victor
DelouvrierInvestor relationsNicolas
MerigeauMedia relations |
|
|
+33 4 78 74 44
38investors@erytech.com |
+33 1 44 71 98 52
erytech@newcap.eu |
PDF available
at: http://ml.globenewswire.com/Resource/Download/a4eda10e-975a-47b5-b896-5ca7af6acea5
Erytech Pharma (NASDAQ:ERYP)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Erytech Pharma (NASDAQ:ERYP)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024